18 research outputs found
PMY Goh, D. Lomanto, JBY So. Robotic-assisted Laparoscopic Cholecystectomy: The First in Asia.
DOI 10.1007/s00464004200
Wellbeing of Surgical Staff since theCOVID-19 Pandemic
10.1002/bjs.11937BRITISH JOURNAL OF SURGERY10711E478-E47
Restructuring the surgical service during the COVID-19 pandemic: experience from a tertiary institution in Singapore
10.1002/bjs.11701BRITISH JOURNAL OF SURGERY1078E252-E252complete
An unfortunate soul: a rare presentation of an uncommon pathology for upper gastrointestinal bleeding
10.1111/ans.14306ANZ journal of surger
Laparoscopic Appendectomy for perforated appendicitis
10.1007/s00268-002-6457-7World Journal of Surgery26121485-1488WJSU
Disruption of her2-induced pd-l1 inhibits tumor cell immune evasion in patient-derived gastric cancer organoids
10.3390/cancers13246158Cancers13246158
Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP).
Objective To investigate the incidence of gastric cancer (GC) attributed to gastric intestinal metaplasia (IM), and validate the Operative Link on Gastric Intestinal Metaplasia (OLGIM) for targeted endoscopic surveillance in regions with low-intermediate incidence of GC.Methods A prospective, longitudinal and multicentre study was carried out in Singapore. The study participants comprised 2980 patients undergoing screening gastroscopy with standardised gastric mucosal sampling, from January 2004 and December 2010, with scheduled surveillance endoscopies at year 3 and 5. Participants were also matched against the National Registry of Diseases Office for missed diagnoses of early gastric neoplasia (EGN).Results There were 21 participants diagnosed with EGN. IM was a significant risk factor for EGN (adjusted-HR 5.36; 95% CI 1.51 to 19.0; pH. pylori. Participants with OLGIM II were also at significant risk of EGN (adjusted-HR 7.34; 95% CI 1.60 to 33.7; p=0.02). A significant smoking history further increases the risk of EGN among patients with OLGIM stages II-IV.Conclusions We suggest a risk-stratified approach and recommend that high-risk patients (OLGIM III-IV) have endoscopic surveillance in 2 years, intermediate-risk patients (OLGIM II) in 5 years